Wow wow wow. We really started the year with a bit of a bang 💥 in women's health last week: In a somewhat historic advancement for women's health, Qvin's received FDA approval of the Q-Pad, an innovative menstrual blood-based health monitoring pad.
Qvin's FDA approval last week was more then just a news story, it's really a narrative shift, positioning menstrual blood at the very center of women's health innovation last week (and beyond).
Qvin showed what's possible when thinking about menstrual blood's role and potential in health diagnostics, and I'm sure this was not the last we'll hear from the company this year. 👀
But let's take a step back. What actually happened last week?
Qvin is a US-based biotech company, that changed the perception of menstrual blood last week, transforming it from a disregarded by-product to a critical health indicator.
Their so-called Q-Pad, a less invasive and more accessible health monitoring tool (read pad), has opened new doors in healthcare, especially for those with limited access to traditional testing methods.
The pad (see image below) includes a removable strip for collecting menstrual blood, which is then sent to a CLIA-Certified laboratory for analysis.
Results are conveniently delivered through the Qvin app. The A1c Q-Pad Test Kit, specifically, measures average blood sugar levels over three months, a critical indicator for diabetes management.
To read the full story on Femtech Insider, click HERE.
Beyond the Basics: The Diagnostic Potential of Menstrual Blood
The scope of menstrual blood in diagnostics is vast and continually expanding. While the Q-Pad is now approved in the context of diabetes management, there's much more on the horizon.
Taking a deeper look, here's an overview of what menstrual blood can potentially diagnose and monitor:
- Reproductive Health: Beyond basic fertility indicators, menstrual blood can reveal intricate details about ovarian reserve, menstrual health, and even the onset of peri-menopause. It offers a monthly snapshot of a woman's reproductive system.
- Hormonal Imbalances: Menstrual blood can provide insights into imbalances in hormones like estrogen and progesterone, which play crucial roles in overall health and well-being.
- Metabolic Syndromes: By analyzing glucose levels and other biomarkers in menstrual blood, it's possible to monitor conditions like diabetes more closely and non-invasively. (see Qvin's FDA approval)
- Cardiovascular Health: Emerging research suggests that menstrual blood could offer indicators for cardiovascular health through specific biomarkers.
- Nutritional Deficiencies and Toxicities: Essential nutrients and potential toxic elements can be traced in menstrual blood, offering a unique perspective on a woman's dietary and environmental exposures.
- Autoimmune Disorders: The presence and levels of certain antibodies in menstrual blood can provide valuable information regarding autoimmune diseases.
- Cancer Detection: Early detection of cancers, particularly gynecological cancers like cervical and ovarian cancer, can be detected through specific markers present in menstrual blood.
Pioneers in Menstrual Blood Diagnostics
While all eyes last week were understandable on Qvin last week, there's more companies that are innovating in this space:
Emm (UK)
Emm was founded in 2020 and will initially provide personalized data and unique insights into menstrual health. It automatically syncs with a smartphone app allowing users to understand their baseline health and spot any changes in patterns or irregularities in their cycle that could indicate a health issue. In its first generation, Emm will monitor menstrual flow rate, volume, length, and regularity. Learn more
theblood (Germany)
theblood's mission is to help people access, understand and benefit from unprecedented data. "We give back self-determination, control, and specific health conditions to our users through a non-invasive menstrual blood test." Learn more
NextGen Jane (US)
NextGen Jane is building a SmartTampon platform that serves as a sentinel system for reproductive health, that will impact how women manage their health, from menarche to post-menopause. Learn more
Yoni Health (UK)
Yoni Health is building Europe's first period biobank. The company is on a mission to revolutionise the healthcare industry, helping businesses and researchers with an interest in women’s health to gain unparalleled insights by providing access to a cutting-edge period biobank. Learn more
Gals Bio (Israel)
Gals Bio's Tulipon is a novel period product that combines the familiar usability of a tampon with an added layer of biomarker monitoring. The first two available biomarkers are the menstrual bleeding amount and vaginal pH. Learn more
The Future Is Now: The Expanding Role of Menstrual Blood in Health
With Qvin's Q-Pad setting the stage, we are currently witnessing a paradigm shift in health diagnostics. While novel, factual and scientific research underpins this advancement: The potential of menstrual blood as a diagnostic tool is supported by emerging research and clinical studies from top institutions, indicating its efficacy in monitoring and diagnosing a range of health conditions.
It is also worth noting that the implications of these advancements extend beyond individual health monitoring. They represent a shift towards more inclusive and accessible healthcare globally. In the context of global health menstrual blood diagnostics can play a crucial role especially in regions where traditional medical infrastructure is limited, offering a simple and non-invasive method to monitor and manage health.
And while the potential of menstrual blood as a diagnostic tool is undoubtedly vast, it's important to acknowledge the challenges ahead as well: Ensuring accuracy, standardizing collection methods, and interpreting results in the context of individual health variations are critical areas for ongoing research and development.
However, these challenges also present opportunities for innovation, collaboration, and further advancements in women's health technology.
I for one can't wait to see what's next in this space! And I'm sure many of you today will feel the same. ✨
